Cellect Biotechnology Company Profile (NASDAQ:APOP)

About Cellect Biotechnology (NASDAQ:APOP)

Cellect Biotechnology logo

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: N/A
  • Sub-Industry: N/A
  • Symbol: NASDAQ:APOP
  • CUSIP: N/A
  • Web: cellectbio.com
Capitalization:
  • Market Cap: $40.89 million
  • Outstanding Shares: 5,379,000
Average Prices:
  • 50 Day Moving Avg: $8.11
  • 200 Day Moving Avg: $7.18
  • 52 Week Range: $2.30 - $13.50
P/E:
  • Trailing P/E Ratio: 44.24
  • Foreward P/E Ratio: -7.16
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $0.92 per share
  • Price / Book: 8.17
Profitability:
  • EBIDTA: ($4,840,000.00)
  • Return on Equity: -99.36%
  • Return on Assets: -76.38%
Debt:
  • Current Ratio: 10.59%
  • Quick Ratio: 10.59%
Misc:
  • Average Volume: 42,876 shs.
  • Short Ratio: 4.28
 
Frequently Asked Questions for Cellect Biotechnology (NASDAQ:APOP)

What is Cellect Biotechnology's stock symbol?

Cellect Biotechnology trades on the NASDAQ under the ticker symbol "APOP."

Where is Cellect Biotechnology's stock going? Where will Cellect Biotechnology's stock price be in 2017?

2 analysts have issued 1-year price objectives for Cellect Biotechnology's shares. Their forecasts range from $1.00 to $10.00. On average, they expect Cellect Biotechnology's stock price to reach $5.50 in the next year. View Analyst Ratings for Cellect Biotechnology.

Who are some of Cellect Biotechnology's key competitors?

How do I buy Cellect Biotechnology stock?

Shares of Cellect Biotechnology can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cellect Biotechnology's stock price today?

One share of Cellect Biotechnology stock can currently be purchased for approximately $7.52.


MarketBeat Community Rating for Cellect Biotechnology (NASDAQ APOP)
Community Ranking:  3.5 out of 5 (   )
Outperform Votes:  26 (Vote Outperform)
Underperform Votes:  11 (Vote Underperform)
Total Votes:  37
MarketBeat's community ratings are surveys of what our community members think about Cellect Biotechnology and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Cellect Biotechnology (NASDAQ:APOP) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $5.50 (26.86% downside)

Analysts' Ratings History for Cellect Biotechnology (NASDAQ:APOP)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
4/4/2017Rodman & RenshawReiterated RatingBuy$10.00 -> $1.00HighView Rating Details
3/27/2017HC WainwrightSet Price TargetBuy$10.00HighView Rating Details
(Data available from 7/24/2015 forward)

Earnings

Earnings History for Cellect Biotechnology (NASDAQ:APOP)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Cellect Biotechnology (NASDAQ:APOP)
Current Year EPS Consensus Estimate: $-0.85 EPS
Next Year EPS Consensus Estimate: $-1.05 EPS

Dividends

Dividend History for Cellect Biotechnology (NASDAQ:APOP)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Cellect Biotechnology (NASDAQ:APOP)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Cellect Biotechnology (NASDAQ:APOP)
Latest Headlines for Cellect Biotechnology (NASDAQ:APOP)
Source:
DateHeadline
streetinsider.com logoCellect Biotechnology (APOP) Granted Russian Patent Covering Any Device & Method Using Flagship Technology
www.streetinsider.com - June 14 at 10:02 AM
finance.yahoo.com logoFollowing the US, Cellect Receives Russian Patent Covering Any Device and Method Using Cellect's Flagship Technology - the ApoGraft™
finance.yahoo.com - June 14 at 10:02 AM
finance.yahoo.com logoCorporate News Blog - Cellect Biotech Gets Patent for Method of Use for Flagship Technology - ApoGraft(TM)
finance.yahoo.com - June 14 at 10:02 AM
finance.yahoo.com logoCellect Receives Notice of Allowance from the US Patent & Trademark Office
finance.yahoo.com - June 12 at 4:39 PM
finance.yahoo.com logoCellect is Moving to Trade Exclusively on the NASDAQ
finance.yahoo.com - June 9 at 3:54 PM
seekingalpha.com logoCellect Bio to delist shares on Tel Aviv exchange; ADRs will continue to trade on Nasdaq
seekingalpha.com - June 5 at 6:19 PM
finance.yahoo.com logoCellect Biotechnology Ltd Provides Corporate Update and Reports First Quarter 2017 Financial Results
finance.yahoo.com - May 29 at 3:57 PM
finance.yahoo.com logoDavid Braun, Head of Merck Device Business (MD&S), Joins Cellect's Advisory Board
finance.yahoo.com - May 23 at 8:41 AM
finance.yahoo.com logoCellect Gets Green Light From FDA For ApoGraft IND Submission in the U.S.
finance.yahoo.com - May 3 at 9:31 AM
finance.yahoo.com logoCellect Biotechnology (APOP) Jumps: Stock Moves 10.5% Higher
finance.yahoo.com - April 7 at 6:44 AM
finance.yahoo.com logoQ1 Roundup: Winners and Losers of Biotech Sector
finance.yahoo.com - April 7 at 6:44 AM
americanbankingnews.com logoCellect Biotechnology Ltd. - American Depositary Shares (APOP) Earns Buy Rating from Rodman & Renshaw
www.americanbankingnews.com - April 4 at 1:23 PM
investopedia.com logoCellect Biotechnology Gets European Patent
www.investopedia.com - April 3 at 8:53 PM
us.rd.yahoo.com logoCellect Receives Notice of Intention to Grant from European Patent Office for Patent Protecting Company’s Technology in Multiple Indications
us.rd.yahoo.com - April 3 at 3:52 PM
finance.yahoo.com logoCellect Biotechnology and Impax Laboratories Post Solid Gains
finance.yahoo.com - March 28 at 10:13 AM
investopedia.com logoCellect Succeeds in First Stem Cell Transplant
www.investopedia.com - March 27 at 3:41 PM
marketwatch.com logoCellect Biotech stock rises 71% after announcing successful stem cell transplant procedure
www.marketwatch.com - March 27 at 3:41 PM
fool.com logoWhy Cellect Biotechnology Stock Is Skyrocketing Today
www.fool.com - March 27 at 3:41 PM
americanbankingnews.com logoCellect Biotechnology Ltd. - American Depositary Shares (APOP) Given a $10.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - March 27 at 2:49 PM
finance.yahoo.com logoCellect Announces Successful First Cancer Patient Stem Cell Transplant
finance.yahoo.com - March 27 at 7:56 AM
finance.yahoo.com logoCellect Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2016 Financial Results
finance.yahoo.com - March 23 at 3:59 PM
finance.yahoo.com logoMichael Berelowitz MD., Former Head, Clinical Development and Medical Affairs, Pfizer Specialty Care Business Unit Joins Cellect’s Board of Directors
finance.yahoo.com - March 2 at 3:50 PM
finance.yahoo.com logoWorld-Renowned Stem Cell Transplantation Expert joins Cellect’s Advisory Board
finance.yahoo.com - February 23 at 3:36 PM
finance.yahoo.com logoCellect Biotechnology Ltd. (Nasdaq: APOP) to Ring The Nasdaq Stock Market Opening Bell
finance.yahoo.com - February 23 at 3:36 PM
finance.yahoo.com logoCellect to Ring the NASDAQ Stock Market Opening Bell on Friday, February 24th
finance.yahoo.com - February 23 at 3:36 PM
finance.yahoo.com logoCellect Announces Positive Clinical Trial Results
finance.yahoo.com - February 21 at 8:31 AM
finance.yahoo.com logoBiotech Industry Poised for a Breakout in 2017? Today's Reports on Cellect Biotechnology and XOMA
finance.yahoo.com - February 16 at 8:30 AM
finance.yahoo.com logoDual-Listed Cellect to Voluntarily File for Delisting from Tel Aviv Stock Exchange
finance.yahoo.com - February 14 at 4:12 PM
streetinsider.com logoCellect Biotechnology (APOP) Says It Treated First Blood Cancer Patient in Phase I/II Trial of ApoGraft
www.streetinsider.com - February 9 at 1:52 AM
us.rd.yahoo.com logoFirst Cancer Patient Treated In Phase I/II Trial of ApoGraft™
us.rd.yahoo.com - February 8 at 3:47 PM
fool.com logoWhy Cellect Biotechnology Ltd Shares Skyrocketed Higher Today
www.fool.com - February 8 at 3:47 PM
finance.yahoo.com logoMergers & Acquisitions Could be a Key Catalyst for Biotech Stocks in 2017: Today's Reports on Cellect Biotechnology and Celldex Therapeutics
finance.yahoo.com - February 3 at 3:43 PM
streetinsider.com logoCellect Biotechnology (APOP) Names Dr. Yaron Pereg as CDO
www.streetinsider.com - January 31 at 2:38 AM
finance.yahoo.com logoDr. Yaron Pereg Appointed as New Chief Development Officer
finance.yahoo.com - January 30 at 4:36 PM
finanznachrichten.de logoGainers & Losers Of The Day: TBIO, IMMU, SGMO, BIOC, APRI
www.finanznachrichten.de - January 13 at 1:38 AM
rttnews.com logoCellect Biotechnology Ltd. (APOP) Is Surging On Patent News
www.rttnews.com - January 12 at 8:38 PM
us.rd.yahoo.com logoCellect Receives Patent Notice of Allowance from US Patent & Trademark Office Protecting Company’s Technology in Multiple Key Indications
us.rd.yahoo.com - January 12 at 3:37 PM
finance.yahoo.com logoMajor Shareholder Buying Shares
finance.yahoo.com - January 9 at 3:47 PM
seekingalpha.com logoCellect appoints Eyal Leibovitz as CFO
seekingalpha.com - January 4 at 2:13 AM
streetinsider.com logoCellect Biotechnology Ltd. (APOP) Names Eyal Leibovitz as CFO
www.streetinsider.com - January 4 at 2:13 AM
us.rd.yahoo.com logoCellect Announces Appointment of Eyal Leibovitz, Experienced Life Sciences Industry and Financial Executive, as Chief Financial Officer
us.rd.yahoo.com - January 3 at 4:08 PM
us.rd.yahoo.com logo8:04 am Cellect Biotechnology appoints Eyal Leibovitz as CFO
us.rd.yahoo.com - January 3 at 4:08 PM
finance.yahoo.com logoLifeSci Capital Initiates Coverage of Cellect Biotechnology
finance.yahoo.com - December 7 at 9:04 PM
finance.yahoo.com logoCellect Biotechnology Ltd Provides Corporate Update and Reports Third Quarter 2016 Financial Results
finance.yahoo.com - November 29 at 2:38 PM
finance.yahoo.com logoCellect signs agreement with the Hadassah Technological Transfer Company – Hadasit
finance.yahoo.com - November 23 at 12:46 PM
finance.yahoo.com logo10:47 am Cellect Biotechnology (thinly-traded) signs agreement with Hadasit for a series of trials using its ApoGraft method to test engraftment potential and its effect on lowering GvHD in mice models
finance.yahoo.com - November 23 at 12:46 PM
finance.yahoo.com logoCoverage initiated on Cellect Biotechnology by Rodman & Renshaw
finance.yahoo.com - November 10 at 2:02 PM
streetinsider.com logoForm 6-K Cellect Biotechnology For: Sep 26
www.streetinsider.com - September 26 at 8:16 AM

Social

Chart

Cellect Biotechnology (APOP) Chart for Monday, July, 24, 2017

This page was last updated on 7/24/2017 by MarketBeat.com Staff